Trial Profile
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Ciclosporin; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease; Transplant rejection
- Focus Registrational; Therapeutic Use
- Acronyms ABA2; GVHD-1
- 15 Jun 2023 Results of abatacept pharmacokinetics , examining abatacept exposure-response (E-R) relationships impact on key clinical outcomes, published in the Blood
- 25 Apr 2023 Planned End Date changed from 1 Feb 2023 to 1 Sep 2023.
- 28 Aug 2022 Results of a descriptive analysis comparing efficacy data collected in a clinical trial setting versus a registry study setting in HSCT recipients presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management